NSE: AKUMS | BSE: 544222

Mid-range Performer

Download real time

447.35 -4.50 (-1.00%)

31.46% Fall from 52W High

68,093 NSE+BSE Volume

NSE 05 Jan, 2026 3:31 PM (IST)

7,041

Market Cap

Above industry Median

Beta 1Year

Very High Volatility

Akums Drugs & Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AKUMS, BSE:544222 Akums Drugs & Pharmaceuticals Ltd.

Search Inside the pdf :

Akums Drugs & Pharmaceuticals Ltd.

22 Dec 2025

447.35

-1.00%

Striving for a turn around

Buy: Akums Drugs & Pharmaceutic...

Target

ICICI Securities Limited

Slump in price of key APIs has exerted pressure on growth in Akums CDMO segment for the past several quarters, we believe this trend is now starting to reverse as API prices are now stabilizing.

Akums Drugs & Pharma has lost -29.42% in the last 1 Year

Akums Drugs & Pharmaceuticals Ltd.

15 Nov 2025

447.35

-1.00%

Export business poised for strong growth ahead

Buy: Akums Drugs & Pharmaceutic...

Target

ICICI Securities Limited

Akums Drugs and Pharmaceuticals (Akums)’s Q2FY26 performance was marred by pricing pressure in API and cost escalation on overheads of new plants. Volumes for the CDMO business, though, continue to grow (7% growth in Q2) despite flattish volumes for market.

Number of FII/FPI investors decreased from 85 to 74 in Sep 2025 qtr

Akums Drugs & Pharmaceuticals Ltd.

11 Aug 2025

447.35

-1.00%

Pricing pressure delays recovery in base biz

Buy: Akums Drugs & Pharmaceutic...

Target

ICICI Securities Limited

Akums Drugs and Pharmaceuticals (Akums)’s Q1FY26 revenue was muted due to slowdown across verticals; however, better product mix aided gross margin expansion (+170bps YoY).

Akums Drugs & Pharmaceuticals Ltd. is trading below its 100 day SMA of 451.4

Akums Drugs & Pharmaceuticals Ltd.

17 Mar 2025

447.35

-1.00%

Aiming for profitable growth ahead

Buy: Akums Drugs & Pharmaceutic...

ICICI Securities Limited

We recently hosted Akums’ management for a roadshow. Akums has been able to maintain its CDMO and overall EBITDA margin at 15.5%/12.0% despite its sub-par revenue growth in 9MFY25. Further efforts towards curbing losses in API division and new export order (starting CY27) could drive operating leverage and boost margins in coming years.

Akums Drugs & Pharma.. has an average target of 600.00 from 1 broker.

Akums Drugs & Pharmaceuticals Ltd.

09 Feb 2025

447.35

-1.00%

On the path to recovery

Buy: Akums Drugs & Pharmaceutic...

ICICI Securities Limited

Akums Drugs and Pharmaceuticals (Akums) in Q3FY25 saw its CDMO business’ volumes recovering (+0.6% YoY). Growth in CDMO should pick up in the next few quarters given Akums’ healthy order book alongside API prices also settling.

Akums Drugs & Pharma has lost -22.67% in the last 6 Months

Akums Drugs & Pharmaceuticals Ltd.

30 Jul 2024

447.35

-1.00%

Akums Drugs and Pharmaceuticals Limited IPO Note

IPO Subscribe: Akums Drugs & Pharmaceutic...

SBI Securities

Akums Drugs & Pharmaceuticals Ltd.'s price crossed below 100Day SMA today

Akums Drugs & Pharmaceuticals Ltd.

29 Jul 2024

447.35

-1.00%

Akums Drugs and Pharmaceuticals Limited - IPO Note - 30072024

IPO Note: Akums Drugs & Pharmaceutic...

HDFC Securities

Akums Drugs and Pharmaceuticals Limited - IPO Note Issue Snapshot: Issue Open: July 30 August 01, 2024 Price Band: Rs. 646 679 (Discount of Rs 64 per share for all eligible employees) *Issue Size: Up to Rs 1856.7 cr (including Fresh issue of Rs 680 cr + Offer for sale of 17,330,435 eq share including employee reservation of upto Rs.15 cr Reservation for: QIB atleast 75% eq sh Non-Institutional upto 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail upto 10% eq sh Face Value: Rs 2 Book value: Rs 49.59 (March 31, 2024) Bid size: - 22 equity shares and in multiples thereof 100% Book built Issue